Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

17.19
+1.177.30%
Post-market: 17.190.00000.00%19:30 EDT
Volume:353.91K
Turnover:6.02M
Market Cap:646.71M
PE:-9.99
High:17.35
Open:16.18
Low:15.88
Close:16.02
52wk High:17.35
52wk Low:8.60
Shares:37.62M
Float Shares:27.82M
Volume Ratio:0.42
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.70
PE(LYR):-7.92

Loading ...

Company Profile

Company Name:
Contineum Therapeutics, INC.
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
51
Office Location:
3565 General Atomics Court,Suite 200,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Contineum Therapeutics, Inc. was incorporated in Delaware in 2009, originally as Versense Pharmaceuticals, Inc., and adopted its current name in November 2023 following several mergers and name changes. The company is a clinical-stage biopharmaceutical company focused on developing differentiated oral small molecule therapies for neuroinflammatory and immunological indications with significant unmet needs. Its pipeline includes the wholly owned candidate PIPE-791 for idiopathic pulmonary fibrosis and chronic pain, as well as the partnered candidate PIPE-307 for depression and multiple sclerosis.

Directors

Name
Position
Carmine Stengone
Chief Executive Officer, President and Director
Evert Schimmelpennink
Chair of the Board
Clare R. Ozawa
Director
Lori M. Lyons Williams
Director
Olivia Ware
Director
Stefan M. Larson
Director
Todd R. Brady
Director

Shareholders

Name
Position
Carmine Stengone
Chief Executive Officer, President and Director
Peter T. Slover
Chief Financial Officer
Stephen L. Huhn
Chief Medical Officer and Senior Vice President, Clinical Development
Daniel S. Lorrain
Chief Science Officer